
Bill Anderson, Bayer CEO (Krisztian Bocsi/Bloomberg via Getty Images)
'Inferior efficacy' leads to premature end of PhIII for Bayer's next-gen blood thinner asundexian
Bayer is bringing a Phase III trial for its blood thinner asundexian to an early end after the drug showed “inferior efficacy” against the control …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.